Skip to Content
Developmental Therapeutics Program (DTP)
Last Updated: 11/16/15

Drug Synthesis and Chemistry Branch (DSCB)

The Drug Synthesis and Chemistry Branch is responsible for the following activities in support of the discovery and development of novel anti-cancer agents:

  1. Worldwide scientific liaison activities with universities and industries to stimulate the submission of a wide variety of synthetic compounds, and pure natural products for in vitro anti-cancer screening
  2. Management of the acquisition, synthesis, storage, inventory, documentation, and distribution of chemical samples for research purposes to NIH and external investigators
  3. Acquisition of pre-clinical and clinical anti-cancer small-molecule chemotherapeutics for evaluation in the NCI-60 cell-line screen
  4. Synthetic and medicinal chemistry resource and expertise in support of NExT development and discovery projects.

Organization

Name Position Email
Joel Morris, Ph.D. Branch Chief joel.morris@nih.gov
Prabhakar Risbood, Ph.D. Chemist risboodp@mail.nih.gov
Stephen L. White, Ph.D. Chemist whitesl@mail.nih.gov
Donn G. Wishka Chemist donn.wishka@nih.gov
Mark Kunkel, Ph.D. Biologist kunkelm@mail.nih.gov
Bill Moore, Ph.D. Head, Laboratory of
Synthetic Chemistry, Leidos
moorewj@mail.nih.gov

Mailing Address:

Dr. Joel Morris, Branch Chief
National Cancer Institute
DTP/DSCB
9609 Medical Center Drive
Rm 4W128/MSC 9734
Bethesda, MD 20892

Express Mail and Courier Address:

Dr. Joel Morris, Branch Chief
National Cancer Institute
DTP/DSCB
9609 Medical Center Drive
Rm 4W128/MSC 9734
Bethesda, MD 208502
Email: ncidtpinfo@mail.nih.gov

About the Branch Chief

Joel Morris Joel Morris serves as Chief of the Drug Synthesis & Chemistry Branch (DSCB), Developmental Therapeutics Program at the National Cancer Institute. Prior to his current appointment in 2010, Dr. Morris spent a significant tenure in the pharmaceutical industry as a Senior Scientist with The Upjohn Company/Pharmacia & Upjohn, and as a Research Fellow with Pfizer. More…